Skye Bioscience, Common Stock Today
| SKYE Stock | USD 2.86 0.15 4.98% |
Performance0 of 100
| Odds Of DistressLess than 34
|
Skye Bioscience, is trading at 2.86 as of the 19th of December 2024, a 4.98 percent decrease since the beginning of the trading day. The stock's lowest day price was 2.8. Skye Bioscience, has about a 34 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 30th of December 2022 and ending today, the 19th of December 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 2nd of April 2015 | Category Healthcare | Classification Health Care |
Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. Skye Bioscience, Inc. was founded in 2012 and is headquartered in San Diego, California. Skye Bioscience operates under Biotechnology classification in the United States and is traded on OTC Exchange. The company has 30.34 M outstanding shares of which 1.59 M shares are at this time shorted by private and institutional investors with about 5.76 trading days to cover. More on Skye Bioscience, Common
Moving against Skye Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Skye Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President Chairman | Punit BA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsSkye Bioscience, can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Skye Bioscience,'s financial leverage. It provides some insight into what part of Skye Bioscience,'s total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Skye Bioscience, Common (SKYE) is traded on NASDAQ Exchange in USA. It is located in 11250 El Camino Real, San Diego, CA, United States, 92130 and employs 11 people. Skye Bioscience, is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 163.52 M. Skye Bioscience, Common conducts business under Biotechnology sector and is part of Health Care industry. The entity has 30.34 M outstanding shares of which 1.59 M shares are at this time shorted by private and institutional investors with about 5.76 trading days to cover.
Skye Bioscience, Common currently holds about 2.93 M in cash with (13.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01.
Check Skye Bioscience, Probability Of Bankruptcy
Ownership AllocationSkye Bioscience, Common shows a total of 30.34 Million outstanding shares. The majority of Skye Bioscience, Common outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Skye Bioscience, to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Skye Bioscience, Common. Please pay attention to any change in the institutional holdings of Skye Bioscience, Common as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Skye Ownership Details
Skye Bioscience, Historical Income Statement
Skye Stock Against Markets
Skye Bioscience, Corporate Management
| BA BA | President, Chairman | Profile | |
| Kaitlyn CPA | Chief Officer | Profile | |
| FACE MD | Chief Officer | Profile | |
| Tu MSc | Chief Officer | Profile | |
| Christopher Twitty | Chief Officer | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Skye Bioscience, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Skye Bioscience,. If investors know Skye will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Skye Bioscience, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.60) | Return On Assets (0.30) | Return On Equity (0.55) |
The market value of Skye Bioscience, Common is measured differently than its book value, which is the value of Skye that is recorded on the company's balance sheet. Investors also form their own opinion of Skye Bioscience,'s value that differs from its market value or its book value, called intrinsic value, which is Skye Bioscience,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Skye Bioscience,'s market value can be influenced by many factors that don't directly affect Skye Bioscience,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Skye Bioscience,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Skye Bioscience, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Skye Bioscience,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.